Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

Abstract Background and Aims Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II. Methods...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of Crohn's and colitis 2021-06, Vol.15 (6), p.938-949
Hauptverfasser:	Reinisch, Walter, Sandborn, William J, Danese, Silvio, Hébuterne, Xavier, Kłopocka, Maria, Tarabar, Dino, Vaňásek, Tomáš, Greguš, Miloš, Hellstern, Paul A, Kim, Joo Sung, Sparrow, Miles P, Gorelick, Kenneth J, Hoy, Michael, Goetsch, Martina, Bliss, Caleb, Gupta, Charu, Cataldi, Fabio, Vermeire, Séverine
Format:	Artikel
Sprache:	eng
Schlagworte:	Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!